$BKUH
Bakhu Holdings, Corp.

2022 Q4 Form 10-Q Financial Statement

#000109690622003010 Filed on December 20, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2021 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.989M $5.269M
YoY Change -5.32% 2845.49%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $33.42K $0.00
YoY Change
% of Gross Profit
Operating Expenses $5.022M $5.269M
YoY Change -4.69% 2845.49%
Operating Profit -$5.022M -$5.269M
YoY Change -4.69%
Interest Expense $46.66K -$27.63K
YoY Change -268.89% 319.27%
% of Operating Profit
Other Income/Expense, Net $4.528M $4.638M
YoY Change -2.38%
Pretax Income -$5.135M -$5.297M
YoY Change -3.06% 2755.74%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.135M -$5.297M
YoY Change -3.06% 2755.74%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$17.04K -$17.61K
COMMON SHARES
Basic Shares Outstanding 301.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.11K $1.159M
YoY Change -98.26% 134655.81%
Cash & Equivalents $20.11K $1.159M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.11K $1.159M
YoY Change -98.26% 134655.81%
LONG-TERM ASSETS
Property, Plant & Equipment $568.1K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $568.1K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $20.11K $1.159M
Total Long-Term Assets $568.1K $0.00
Total Assets $588.2K $1.159M
YoY Change -49.24% 134655.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.589M $774.8K
YoY Change 105.12% 766.8%
Accrued Expenses $265.6K $109.6K
YoY Change 142.3% 413.88%
Deferred Revenue
YoY Change
Short-Term Debt $6.593M $2.137M
YoY Change 208.45% 198.42%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.447M $3.022M
YoY Change 179.56% 265.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.447M $3.022M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $8.447M $3.022M
YoY Change 179.56% 265.42%
SHAREHOLDERS EQUITY
Retained Earnings -$48.66M
YoY Change
Common Stock $301.3K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.859M -$1.863M
YoY Change
Total Liabilities & Shareholders Equity $588.2K $1.159M
YoY Change -49.24% 134655.81%

Cashflow Statement

Concept 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$5.135M -$5.297M
YoY Change -3.06% 2755.74%
Depreciation, Depletion And Amortization $33.42K $0.00
YoY Change
Cash From Operating Activities -$221.2K -$550.5K
YoY Change -59.81% 216.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $10.13K
YoY Change
Cash From Investing Activities $10.13K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.456M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $218.8K 1.663M
YoY Change -86.84% 972.59%
NET CHANGE
Cash From Operating Activities -$221.2K -550.5K
Cash From Investing Activities $10.13K $0.00
Cash From Financing Activities $218.8K 1.663M
Net Change In Cash $7.662K 1.112M
YoY Change -99.31% -5983.44%
FREE CASH FLOW
Cash From Operating Activities -$221.2K -$550.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-10-31
CY2022Q4 dei Entity File Number
EntityFileNumber
000-55862
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
BAKHU HOLDINGS, CORP.
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0510649
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
One World Trade Center
CY2022Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 130
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90831
CY2022Q4 dei City Area Code
CityAreaCode
858
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
682-2548
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q4 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
301302983 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20113 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12451 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20113 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
12451 usd
CY2022Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
100254 usd
CY2022Q3 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
76516 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
568104 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
688644 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
568104 usd
CY2022Q3 us-gaap Other Assets
OtherAssets
688644 usd
CY2022Q4 us-gaap Assets
Assets
588217 usd
CY2022Q3 us-gaap Assets
Assets
701095 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1589326 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1265968 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
265582 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
218919 usd
CY2022Q4 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
6592515 usd
CY2022Q3 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
6373731 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8447423 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7858618 usd
CY2022Q4 us-gaap Liabilities
Liabilities
8447423 usd
CY2022Q3 us-gaap Liabilities
Liabilities
7858618 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
301282983 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
301282983 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
301282983 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
301282983 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
301283 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
301283 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40503705 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
36070822 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48664194 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43529628 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7859206 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-7157523 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
588217 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
701095 usd
CY2022Q4 us-gaap Revenues
Revenues
0 usd
CY2021Q4 us-gaap Revenues
Revenues
0 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
4432883 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
4443406 usd
CY2022Q4 us-gaap Other Expenses
OtherExpenses
4528000 usd
CY2021Q4 us-gaap Other Expenses
OtherExpenses
4638441 usd
CY2022Q4 us-gaap Professional Fees
ProfessionalFees
170223 usd
CY2021Q4 us-gaap Professional Fees
ProfessionalFees
248655 usd
CY2022Q4 us-gaap Depreciation
Depreciation
33418 usd
CY2021Q4 us-gaap Depreciation
Depreciation
0 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
290514 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
382096 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
5022155 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
5269192 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5022155 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5269192 usd
CY2022Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
65748 usd
CY2021Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
46663 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
27627 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112411 usd
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27627 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5134566 usd
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5296819 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5134566 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-5296819 usd
CY2022Q4 fil Basic Net Loss Per Share
BasicNetLossPerShare
-0.02
CY2021Q4 fil Basic Net Loss Per Share
BasicNetLossPerShare
-0.02
CY2022Q4 fil Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
301282983 shares
CY2021Q4 fil Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
300856133 shares
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5134566 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-5296819 usd
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-4432883 usd
CY2021Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-4443406 usd
CY2022Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
65748 usd
CY2021Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
CY2022Q4 us-gaap Depreciation
Depreciation
33418 usd
CY2021Q4 us-gaap Depreciation
Depreciation
0 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
334607 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
275246 usd
CY2022Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
46663 usd
CY2021Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
27627 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-221247 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-550540 usd
CY2022Q4 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10125 usd
CY2021Q4 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10125 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1662510 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7662 usd
CY2021Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1456003 usd
CY2022Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2883 usd
CY2021Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2022Q4 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
221667 usd
CY2021Q4 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
206507 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
218784 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1111970 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12451 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46929 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20113 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1158899 usd
CY2022Q4 us-gaap Interest Paid
InterestPaid
0 usd
CY2021Q4 us-gaap Interest Paid
InterestPaid
0 usd
CY2022Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2021Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-7157523 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
4432883 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5134566 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7859206 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-2465421 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
4443406 usd
CY2021Q4 fil Stock Issued For Cash
StockIssuedForCash
-1456003 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-5296819 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1862831 usd
CY2022Q4 us-gaap Nature Of Operations
NatureOfOperations
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;text-indent:-27.35pt;margin-left:27.35pt;text-align:justify"><b>NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS; BASIS OF PRESENTATION</b></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;text-indent:-27pt;margin-left:63.1pt;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">Bakhu Holdings, Corp. (formerly Planet Resources, Corp.) (the “Company”) was incorporated under the laws of the State of Nevada, U.S. on April 24, 2008. In May 2009, the Company began to look for other types of business to pursue that would benefit the stockholders. To pursue businesses outside the mining industry the name of the Company was changed with the approval of the directors and stockholders to Bakhu Holdings, Corp. on May 4, 2009.</p> <p style="font:10pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">The Company has not generated any revenue to date, and consequently, its operations are subject to all risks inherent in establishing a new business enterprise. For the period from inception, April 24, 2008, through October 31, 2022, the Company had accumulated losses of $48,664,194.</p> <p style="font:10pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">The Company holds a license from Cell Science Holding Ltd., an affiliate (“Cell Science”), to plant cell replication technology and related proprietary equipment, processes, and formulations to produce, manufacture, and sell cannabis-related byproducts—sometimes referred to as cannabinoids—exclusively in North and Central America and the Caribbean for medical, food additive, and recreational uses.</p> <p style="font:10pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">On August 9, 2019, the Company formed Cell Science CBD International, Inc., a California corporation as a wholly owned subsidiary to commercialize use of the licensed technology to produce and manufacture cannabis and their byproducts that have measurable tetrahydrocannabinol (THC) concentration potency less than 3% on a dry weight basis. This subsidiary had no active operations as of October 31, 2022. When used herein, the “Company” includes this consolidated subsidiary.</p> <p style="font:10pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin:0;text-align:justify">In the opinion of management, the Company’s financial statements reflect all adjustments that are of a normal recurring nature necessary for presentation of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with the instructions to Form 10-Q in Article 10 of SEC Regulation S-X. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. As used in this report, the term the “Company” means Bakhu Holdings, Corp. and its subsidiary, unless the context indicates otherwise.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;text-align:justify">The Company condensed or omitted certain information and footnote disclosures normally included in our annual audited financial statements, which the Company prepared in accordance with GAAP. Our interim financial statements should be read in conjunction with our annual report on Form 10-K for the year ended July 31, 2022.</p>
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q4 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2008-04-24
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48664194 usd
CY2022Q4 fil Share Based Compensation Arrangement By Share Based Payment Award Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised
0 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
100000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12318085 shares
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;margin-left:0.3pt;text-align:justify"><span style="border-bottom:1px solid #000000">Use of Estimates and Assumptions</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;text-indent:-27pt;margin-left:63.2pt;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;margin-left:0.2pt;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1200000 shares
CY2022Q4 us-gaap Fiscal Period
FiscalPeriod
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;margin-left:0.7pt;text-align:justify"><span style="border-bottom:1px solid #000000">Fiscal Periods</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;margin-left:0.7pt;text-align:justify"> </p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:0.1pt;margin-left:0.7pt;text-align:justify">The Company’s fiscal year end is July 31.</p>
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
668358 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
765160 usd
CY2022Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
100254 usd
CY2022Q3 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
76516 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
568104 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
688644 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 fil Stock Issued For Cash Shares
StockIssuedForCashShares
88334 shares
CY2020Q3 fil Stock Issued For Cash
StockIssuedForCash
-265000 usd
CY2022Q4 fil Stock Issued For Cash Shares
StockIssuedForCashShares
485001 shares
CY2021Q4 fil Stock Issued For Cash
StockIssuedForCash
-1456003 usd
CY2022Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
100002 shares
CY2022Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
150001 usd
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20000000 shares
CY2021Q4 fil Share Based Compensation Arrangement By Share Based Payment Award Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised
-800000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.10
CY2021Q4 fil Shares Canceled In Payment Of The Aggregate Exercise Price
SharesCanceledInPaymentOfTheAggregateExercisePrice
304354 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12418085 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2942515 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
250324 usd
CY2022Q4 fil License Fee
LicenseFee
250000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
765161 usd
CY2021Q4 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
2734839 usd

Files In Submission

Name View Source Status
0001096906-22-003010-index-headers.html Edgar Link pending
0001096906-22-003010-index.html Edgar Link pending
0001096906-22-003010.txt Edgar Link pending
0001096906-22-003010-xbrl.zip Edgar Link pending
bakh_ex31z1.htm Edgar Link pending
bakh_ex31z2.htm Edgar Link pending
bakh_ex32.htm Edgar Link pending
bkhu-20221031.htm Edgar Link pending
bkhu-20221031.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bkhu-20221031_def.xml Edgar Link unprocessable
bkhu-20221031_lab.xml Edgar Link unprocessable
bkhu-20221031_pre.xml Edgar Link unprocessable
bkhu-20221031_cal.xml Edgar Link unprocessable
bkhu-20221031_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending